Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29002686 | 0.80 | TAAR1 (0.54) | HRH1HTR2ATAAR1LMNA | |
| SCHEMBL11092760 | 0.79 | HRH1 (0.52) | SLC7A5HRH1HTR2ATAAR1SIGMAR1 | |
| SCHEMBL3765092 | 0.77 | HRH1 (0.50) | SLC7A5HRH1HTR2ATAAR1KIF11 | |
| SCHEMBL18863924 | 0.77 | LMNA (0.41) | HRH1HTR2ATAAR1LMNA | |
| SCHEMBL9846077 | 0.77 | TAAR1 (0.50) | HRH1HTR2ATAAR1LMNA | |
| SCHEMBL14387157 | 0.76 | TAAR1 (0.59) | SLC7A5HRH1HTR2ATAAR1MAOA | |
| SCHEMBL3428511 | 0.76 | TAAR1 (0.59) | SLC7A5HRH1HTR2ATAAR1MAOA | |
| Benzene SCHEMBL27904738 | 0.75 | HTR2A (0.52) | SLC7A5HRH1HTR2ATAAR1SIGMAR1 | |
| SCHEMBL335854 | 0.74 | LMNA (0.42) | HRH1HTR2ATAAR1LMNA | |
| SCHEMBL14459040 | 0.74 | TAAR1 (0.57) | SLC7A5HRH1HTR2ATAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | SLC7A5 4096/4885HRH1 4875/4885HTR2A 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.